NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

CompletedN/A

Sponsor: AstraZeneca

Conditions: Metastatic Breast Cancer

Interventions: non-interventional

Countries: United States

A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria (self-reported):

* Adult (over the age of 18 years)
* Diagnosed with HR+/HER2- metastatic breast cancer
* Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)

Exclusion criteria (self-reported):

* Patients who had discontinued capivasertib for more than 6 months before the date of the interview
* Unable or unwilling to follow study procedures (including providing informed consent)
* Not proficient in spoken English, as assessed by the moderator
* Receiving capivasertib in a clinical trial setting
* Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)

Locations (1)

Redwood Shores, California, United States